Different adjuvanted pediatric HIV envelope vaccines induced distinct plasma antibody responses despite similar B cell receptor repertoires in infant rhesus macaques.

Stella J. Berendam^{1,#}, Papa K Morgan-Asiedu^{1,#}, Riley J. Mangan¹, Shukhang Li¹, Holly Heimsath¹, Kan Luo¹, Alan D. Curtis II², Joshua A. Eudailey^{1,8}, Christopher B. Fox^{3,4}, Mark A. Tomai⁵, Bonnie Phillips², Hannah L. Itell¹, Erika Kunz¹, Michael Hudgens⁶, Kenneth Cronin¹, Kevin Wiehe¹, S.Munir Alam¹, Koen K.A. Van Rompay⁷, Kristina De Paris², Sallie R. Permar^{1,8}, M. Anthony Moody^{1,*}, and Genevieve G. Fouda^{1,*}

¹Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA

²Department of Microbiology and Immunology, Children's Research Institute and Center for AIDS Research, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

³Infectious Disease Research Institute (IDRI), Seattle, Washington State, USA

⁴Department of Global Health, University of Washington, Seattle, Washington State, USA

⁵3M Drug Delivery Systems, 3M center, St. Paul, Minnesota, USA

⁶Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

⁷California National Primate Research Center, University of California at Davis, Davis, California, USA

⁸Department of Pediatrics, Weill Cornell College of Medicine, New York City, New York, USA

Corresponding author: Genevieve G. Fouda (genevieve.fouda@duke.edu)

[#]Shared first authorship. SJB performed data analysis, designed figures, and wrote the manuscript. PKMA performed experiments and contributed to the writing of the manuscript.

^{*}Shared last authorship. GGF and MAM contributed equally to design of the experiments and manuscript editing.

Abstract

Different HIV vaccine regimens elicit distinct plasma antibody responses in both human and nonhuman primate models. Previous studies in human and non-human primate infants showed that adjuvants influenced the quality of plasma antibody responses induced by pediatric HIV envelope vaccine regimens. We recently reported that use of the 3M052-SE adjuvant and longer intervals between vaccinations are associated with higher magnitude of antibody responses in infant rhesus macaques. However, the impact of different adjuvants in HIV vaccine regimens on the developing infant B cell receptor (BCR) repertoire has not been studied. This study evaluated whether pediatric HIV envelope vaccine regimens with different adjuvants induced distinct antigen-specific memory B cell repertoires and whether specific immunoglobulin (Ig) immunogenetic characteristics are associated with higher magnitude of plasma antibody responses in vaccinated infant rhesus macaques. We utilized archived preclinical pediatric HIV vaccine studies PBMCs and tissue samples from 19 infant rhesus macaques immunized either with (i) HIV Env protein with a squalene adjuvant, (ii) MVA-HIV and Env protein coadministered using a 3-week interval, (iii) MVA-HIV prime/ protein boost with an extended 6-week interval between immunizations, or (iv) with HIV Env administered with 3M-052-SE adjuvant. Frequencies of vaccine-elicited HIV Env-specific memory B cells from PBMCs and tissues were similar across vaccination groups (frequency range of 0.06-1.72%). There was no association between vaccine-elicited antigen-specific memory B cell frequencies and plasma antibody titer or avidity. Moreover, the epitope specificity and Ig immunogenetic features of vaccine-elicited monoclonal antibodies did not differ between the different vaccine regimens. These data suggest that pediatric HIV envelope vaccine candidates with different adjuvants that previously induced higher magnitude and quality of plasma antibody responses in infant rhesus macaques were not driven by distinct antigen-specific memory BCR repertoires.

Introduction

In 2019, 85% of the estimated 1.3 million pregnant women living with HIV-1 globally received antiretroviral drugs to prevent transmission to their children (1). While the implementation of antiretroviral prophylaxis has significantly decreased the global frequency of mother-to-child transmission (MTCT) of HIV-1, issues of maternal adherence to antiretroviral therapy (ART) (2, 3), development of ART-resistant viruses (4), and insufficient coverage of ART in some of the hardest-hit areas globally have limited the effectiveness of ART (5). Furthermore, women with acute HIV-1 infection in late pregnancy or during the breastfeeding period are less likely to be diagnosed and receive treatment to prevent MTCT (6). Thus, despite advancements in therapy, breast milk transmission still accounts for approximately 50% of pediatric HIV infections (7, 8). Additional prevention strategies, such as a pediatric HIV-1 vaccine, are therefore critically needed to eradicate breast milk transmission of HIV-1.

Early efforts in HIV-1 vaccine development focused on the humoral arm of the immune system as other vaccines that successfully prevent viral diseases relied on antibodies for protection (9). However, early-phase HIV-1 vaccine studies using recombinant HIV-1 envelope (Env) proteins showed no efficacy (10-12) with the exception of the RV144 trial that demonstrated moderate vaccine efficacy of 61% during the first year and an overall efficacy of 31% at 3.5 years after vaccination (13, 14). Interestingly, non-neutralizing IgG that targeted the

HIV-1 Env variable loops 1 and 2 (V1V2) were identified as correlates of protection from the RV144 study; meanwhile HIV-1 Env-specific IgA plasma antibodies were associated with lack of protection (15). This finding reinvigorated the optimism that an effective HIV-1 vaccine is attainable. A phase 2b/3 study (HVTN 702 or Uhambo) in South Africa, which used a pox vector prime-protein boost vaccine regimen similar to RV144, albeit with distinct vaccine strains and a different adjuvant, did not reproduce the results from the RV144 study and showed no efficacy (16). Nevertheless, these studies demonstrated that HIV-1 vaccine immunogens could induce robust levels of V1V2 IgG antibodies as well as polyfunctional CD4⁺ T cell responses as surrogate of possible protection (15, 17).

To date, only a few previous pediatric HIV-1 vaccine trials have been conducted and these trials demonstrated that immunization with recombinant subunit HIV gp120 vaccines (PACTG 230) or with canarypox vectors expressing HIV antigens (PACTG 326, HPTN 027) are safe and immunogenic (18-21). Importantly, HIV-1 infant vaccination with MF-59 adjuvanted HIV gp120 was able to generate robust and durable Env-specific IgG responses including anti-V1V2 IgG responses with low levels of Env-specific IgA responses (22). Similarly, neonatal rhesus macaques are capable of developing robust virus-specific humoral and cellular immune responses after SIV vaccination (23, 24). These clinical and preclinical studies demonstrate the feasibility of initiating HIV-1 immunization within the first few days of life.

Our previous studies in human and non-human primate infants have indicated that several factors can modulate the quality of the vaccine-elicited antibody response in infants (25, 26). Notably, we observed that extending the interval between immunizations and the use of toll-like receptor (TLR) agonist adjuvants can enhance the magnitude and breadth of the cellular and humoral responses (26, 27). However, the influence of distinct HIV vaccine regimens and adjuvants on the developing infant B cell repertoire has not been studied and the relationship between the magnitude and quality of HIV-1 vaccine-elicited responses and immunogenetic characteristics of the infant B cell repertoire remains unclear. Taking advantage of archived plasma samples obtained from completed preclinical studies (25, 26), we assessed the antigen-specific B cell repertoire in HIV vaccinated infant rhesus macaques. Our results indicated that the magnitude and quality of plasma antibody responses induced by pediatric HIV vaccine regimens with different adjuvants were not associated with distinct B cell repertoire profiles in infant rhesus macaques.

Methods

Animals

A total of 19 Simian Immunodeficiency Virus (SIV)-negative and type D retrovirus-negative newborn Indian-origin rhesus macaques (*Macaca mulatta*) were hand reared in the nursery of the California National Primate Research Center (CNPRC, Davis, CA) as previously described (25). Animals were reared in accordance with the American Association for Accreditation of Laboratory Animal Care Standards, the guidelines of the Guide for the Care and Use of Laboratory Animals of the Institute for Laboratory Research, National Research Council, and the International Guiding Principles for Biomedical Research Involving Animals. All protocols were assessed and approved by the University of California at Davis Institutional Animal Care and Use Committee prior to beginning the study. Animals were randomly assigned to groups and anesthetized for vaccinations and sample collection as previously reported (25, 26).

Immunization regimens and study designs

Immunization regimens and study designs for all 4 animal groups are summarized in Figure 1 and were previously described (25, 26). Briefly, infants in group 1 (protein only, n=5) were vaccinated at 0, 3 and 6 weeks of age intramuscularly (IM) with 5×10^8 infectious units [IU] of MVA/SIV gag/pol, with 15 μ g of C.1086 gp120 administered IM in Span85-Tween 80-squalene (STS) adjuvant, and with 200 μ g of C.1086 gp120 administered intranasally (IN) in Toll-like receptor 7 and 8 (TLR7/8) agonist, R848 adjuvant (25). Infants in group 2 (co-administration, n=5) were vaccinated at 0, 3 and 6 weeks of age with similar regimen as group 1 with addition of the MVA-HIV Env (5×10^8 IU, IM). Infants from these two groups were followed for 19 and 15 weeks, respectively, after which they were euthanized to analyze vaccine-induced tissue responses. Infants in group 3 (extended interval, n=4) received the same vaccine regimen as the co-administration group but were immunized at 0, 6 and 12 weeks and then boosted at 32 before euthanasia at week 35 (25). Infants in group 4 (3M-052-SE, n=4) were immunized at 0, 2 and 6 weeks of age with a combination of HIV.C.1086C gp120 and TV1 gp120 (15 μ g each, IM) in TLR7/8-based adjuvant 3M-052 formulated in stable emulsion (3M-052-SE) (26).

Collection and processing of blood and tissue specimens

Whole blood, plasma, and peripheral blood mononuclear cells (PBMCs) were collected before each immunization and thereafter biweekly throughout the study as previously described (25, 26). PBMCs reported in this study were collected at week 8 for the protein only, coadministration, and extended interval groups. Spleen, lymph nodes (LNs; axillary, mesenteric, submandibular, cervical, submental, and retropharyngeal), and intestinal tissues (colon and ileum) were collected for preparation of mononuclear cell (MNC) suspensions at necropsies for groups 1 to 3 (i.e., the protein only, coadministration, and extended interval groups). LN biopsies were collected at week 10 while PBMCs were collected at week 15 in the 3M-052-SE group.

Single-cell flow cytometry sorting of antigen-specific memory B cells

PBMCs and tissue MNC suspensions were treated with 5 μ M Chk2 inhibitor II or 2-[4-(4-chlorophenoxy)phenyl]-1H-benzimidazole-5-carboxamide (Sigma) prepared in final volume of 1% bovine serum albumin (Sigma-Aldrich) in 1X phosphate buffered saline (PBS, Sigma). PBMCs and MNC suspensions were blocked with 6.25 μ g/ml anti-human CD4 antibody (BD Biosciences) at 4°C for 15 min followed by staining with a panel of fluorochrome-conjugated antibodies to identify antigen-specific memory B cells as described by gating strategy (Supplemental figure 2B). Briefly, lymphocytes were gated on singlets and live cells based on Aqua vital dye (Invitrogen), exclusion of T cells (CD3-PerCP-Cy5.5, clone SP34-2, BD Biosciences) and monocytes/macrophages (CD14-BV570, clone M5E2, BioLegend; CD16-Phycoerythrin-Cy7, clone 3G8, BD Biosciences), followed by selection of memory B cells by positive expression of CD20 and CD27 (CD20-FITC, clone 2H7; CD27-APC-Cy7, clone O323, both BioLegend) but not immunoglobulin D (IgD-PE, Southern Biotech) with double specificity to both HIV C.1086 Env hooks (BV421-gp120 C.1086 and AF647-gp120 C.1086, both generated in-house). Percent of antigen-specific memory B cells from individual infants and tissue types as well as representative flow cytometry analysis for sorting are listed in Supplemental Figure 2A.

Polymerase chain reaction (PCR) amplification of immunoglobulin (Ig) V_H and V_L genes

The sorted single-cell antigen specific memory B cells V_H and V_L genes were amplified by nested PCR as previously described (28-30) followed by Sanger sequencing of the purified nested PCR products. Sequences were analyzed using a custom bioinformatics pipeline and were annotated with immunogenetic information using the Cloanalyzer software package (<https://www.bu.edu/computationalimmunology/research/software/>) (31). Identification of Ig subtypes and functional Ig heavy and light chains were first performed using human Ig sequence database as previously described (28) and recombinant monoclonal antibodies (mAbs) were generated based on this analysis. Subsequently the immunogenetic characteristics of the recombinant mAbs were reanalyzed using a rhesus Ig sequence database once it became available.

Results

Enhancement of pediatric HIV Env antibody responses by extended vaccine interval and TLR agonist adjuvants despite similar antigen-specific memory B cells in PBMC and tissues across vaccination groups.

We have evaluated different vaccine regimens and immunization schedules (Fig 1, see details in methods) to optimize HIV Env-specific antibody responses in infant rhesus macaques (25, 26). Previously, we observed that the magnitude and quality of vaccine-induced HIV Env-specific responses can be enhanced by increasing the timing of vaccination interval from 3 to 6 weeks (25) and by using the TLR7/8 agonist adjuvant 3M-052-SE when compared to alum or to the TLR4 ligand glucopyranosyl lipid formulated in SE (GLA-SE) (26). Overall, infants vaccinated with 3M-052-SE-adjuvanted vaccine developed the highest magnitude of HIV Env C.1086 gp120-specific plasma IgG antibody concentrations across all four groups at peak immunogenicity (S1 Fig A). Additionally, at peak immunogenicity, infant plasma antibody from all four groups developed varying levels of cross clade Env gp120 responses as well as broad heterologous epitope specificities and breadth (S1 Fig B-C). Infant plasma IgG antibody from group 4 (3M-052-SE) also demonstrated higher avidity strengths against the tested antigens (HIV Env 1086d7gp120 K160N and gp70 ConC V3) compared to other immunization groups (S1 Fig D).

Fig 1. Animal study design and immunization schedule. Infant rhesus macaques from four immunization schedules were included. Protein only group was immunized with MVA-SIV gag/pol and HIV Envelope (Env) 1086c adjuvanted with 15 µg STS, intramuscular + 200 µg R848, intranasal. Coadministration group was immunized with MVA-SIV gag/pol, HIV Env 1086c adjuvanted with 15 µg STS, intramuscular + 200 µg R848, intranasal), and with MVA-HIV Env. Extended interval group was immunized with similar immunogens as Coadministration group with longer immunization intervals. 3M-052-SE group was immunized with HIV Env 1086c/TV1 bivalent adjuvanted with 15 µg/15 µg+3M-052-SE, intramuscular.

Plus symbol (+) denoted necropsy, IM denoted intramuscular, IN denoted intranasal, and IU denoted infectious unit.

Single-cell flow cytometry sorting of antigen-specific memory B cells indicated low level of frequencies across all vaccination groups.

To determine whether the different vaccine regimens induced antibodies with distinct frequency of antigen-specific memory B cells, we characterized antigen-specific memory B cells from PBMC and tissues at selected time points (Fig 1). We were able to obtain Env-specific memory B cells (CD3-CD16-CD14-CD20+CD27+IgD-, double positive for HIV Env C.1086 gp120) from 3 of 5 infants in group 1 (protein only), 5 of 5 infants in group 2 (coadministration), 3 of 5 infants in group 3 (extended interval), and from 4 of 4 infants in group 4 (3M-052-SE) (S2 Fig A-B). The frequency of Env-specific memory B cells were low across all vaccine groups (0.06-1.72%) with 0.07-1.72% range in group 1, 0.06-0.97% in group 2, 0.08-0.49% in group 3, and 0.06-0.11% in group 4.

We were able to produce a total of 39 mAbs with functional heavy- and light-chain pairs based on our initial analysis using the human Ig sequence database (28), because rhesus Ig database was unavailable at the time. The 39 mAbs came from 13 specimens including 3 specimens from group 1 (2 infants), 3 specimens from group 2 (2 infants), 4 specimens from group 3 (2 infants), and 3 specimens from group 4 (3 infants) for final B cell repertoire analyses (Table 1). No tissue specimen was available for group 4 as these infants were part of a challenge study. Overall, the frequencies of Env-specific memory B cells in PBMCs and tissues did not differ between the vaccine groups. The percent frequency of antigen-specific memory B cells ranged from 0.06 to 1.72%, with the highest frequency observed in the PBMCs of 2 infants in group 1 (protein only) (S2 Fig A). Notably, despite higher magnitude and quality of Env-specific plasma antibody responses in group 3 (extended interval) compared to group 2 (coadministration) (25), the frequencies of Env-specific memory B cells did not differ between these groups. Similarly, despite higher binding magnitude and avidity strength of Env-specific plasma antibody responses in group 4 (3M-052-SE) when compared to others, the frequencies of Env-specific memory B cells at least in the PBMCs of vaccinated infants in this group did not differ to the other groups. Altogether, these data suggest that the size of HIV Env vaccine-elicited memory B cell pool is not directly related to magnitude or quality of plasma Env-specific antibody responses in infant rhesus macaques.

Table 1. Immunogenetic characteristics of isolated envelope (Env)-reactive mAbs of Env-vaccinated infant monkeys based on human immunoglobulin database analysis. A total of 39 pairs of potentially Env-reactive mAbs were isolated from the four vaccination groups across several anatomic compartments. Frequency of gene usage, percent somatic hypermutation, and complementarity-region 3 (CDR3) length are displayed for the heavy and light chains for each mAb along with the isotype and epitope specificity.

Animal ID	Group	Tissue	IgH ID	V _H gene	D _H gene	J _H gene	HC % SHM	HC CDR3 length	Ig Isotype	IgL ID	V _L /V _K gene	J _L /J _K gene	Specificity
45521	Protein Only	Spleen	H020465	4~4*07	2~OF15*2/inv	3*01	5.31	23	IgG	K020382	1~33*01	2*03	Undetermined

45521	Protein Only	Retropharyngeal LN	H914 640	4~4*07	3~3*01	3*01	6.14	23	IgA	K907 482	1~33*01	2*03	Undetermined
45521	Protein Only	Retropharyngeal LN	H914 648	4~4*07	3~3*01	3*01	6.65	23	IgG	K907 485	1~33*01	2*03	Undetermined
45521	Protein Only	Retropharyngeal LN	H914 649	4~4*07	5~12*01	3*01	5.88	23	IgG	K907 486	1~33*01	2*03	Undetermined
45522	Protein Only	Spleen	H020 414	4~61*03	6~13*01	4*02	10.03	13	IgG	L020 264	1~51*02	3*02	Undetermined
45083	Coadministration	Spleen	H020 400	4~59*01	6~19*01	4*02	6.17	13	IgM	L020 253	1~40*01,02	2*01	V1V2
45083	Coadministration	Mediastinal LN	H020 405	4~59*01,02	3~16*01,02	4*02	4.52	17	IgG	K020 331	1D~16*01	2*03,04	V1V2
45083	Coadministration	Mediastinal LN	H020 405	4~59*01,02	3~16*01,02	4*02	4.52	17	IgG	L020 258	2~23*02	1*01	V3
45083	Coadministration	Mediastinal LN	H020 407	4~b*02	5~12*01	4*02	8.41	13	IgG	L020 260	2~8*01	1*01	V3
45083	Coadministration	Mediastinal LN	H020 408	4~39*06	1~26*01	4*02	6.38	13	IgG	L020 260	2~8*01	1*01	Undetermined
45091	Coadministration	Axillary LN	H020 381	3~73*01,02	2~2*02/inv	6*02	10.15	14	IgG	L020 241	11~55*01	2*01	Undetermined
45091	Coadministration	Axillary LN	H020 387	4~59*01	4~4*01	4*02	4.74	17	IgG	K020 324	1~39*01	4*01	V3
45435	Extended Interval	Mediastinal LN	H020 422	4~59*01	3~3*01,02	3*01,02	6.19	18	IgA	K020 341	1~13*02	4*01	V1V2
45435	Extended Interval	Mediastinal LN	H020 425	4~59*01,02	3~OR15*3	5*01,02	7.63	16	IgG	K020 344	1~33*01	2*03	CD4 binding site
45435	Extended Interval	Mediastinal LN	H020 426	3~72*01	1~OR15*1	6*02	8.30	14	IgM	L020 282	11~55*01	2*01	V3
45435	Extended Interval	Mediastinal LN	H020 430	3~11*01	1~7*01/inv	5*01	10.61	17	IgG	K020 348	1/OR2~0*01	2*03	V1V2
45435	Extended Interval	Mediastinal LN	H020 431	3~64*02	4~17*01	5*01	9.40	12	IgG	K020 349	3~11*01	1*01	V1V2
45435	Extended Interval	Mediastinal LN	H020 445	4~4*02	4~4*01	4*02	6.53	16	IgG	K020 359	1D~16*01	2*03	V3
45435	Extended Interval	Mediastinal LN	H020 420	4~61*05	6~13*01	4*02	11.08	16	IgG	L020 280	5~39*01	2*01	V3
45435	Extended Interval	Spleen	H020 461	3~73*01,02	2~15*01	4*02	9.65	17	IgG	K020 380	1~12*01,02	2*03	Undetermined
45441	Extended Interval	Spleen	H020 449	3~21*01,02	1~IR1*01	1*01	6.05	29	IgG	K020 361	1D~16*01	1*01	Undetermined
45441	Extended Interval	Spleen	H020 452	4~59*01	3~3*01	4*02	7.18	18	IgG	L020 292	1~51*02	7*01	CD4 binding site
45441	Extended Interval	Spleen	H020 450	3~21*01,02	3~22*01	1*01	7.14	15	IgG	L020 290	3~21*01	6*01	Undetermined
45441	Extended Interval	Submental LN	H914 598	4~59*01	3~3*01	6*02	7.41	18	IgA	K907 464	2~28*01	1*01	Undetermined

45838	3M-052-SE	PBMC	H020493	3~43*02	6~13*01	4*02	5.31	10	IgG	L020321	3~19*01	2*01	Undetermined
45840	3M-052-SE	PBMC	H020481	4~61*01,08	3~3*01,02	4*02	6.32	13	IgG	K020401	2~30*01	1*01	V3
45840	3M-052-SE	PBMC	H020485	4~39*06	3~3*01,02	4*02	6.12	13	IgG	K020402	2~40*01	1*01	V3
45840	3M-052-SE	PBMC	H020488	3~43*02	6~13*01	4*02	4.77	10	IgG	K020402	2~40*01	1*01	Undetermined
45851	3M-052-SE	PBMC	H020495	3~15*08	0~1R*01C	3*01	7.03	11	IgG	K020407	2~40*01	1*01	Undetermined
45851	3M-052-SE	PBMC	H020494	4~39*06	3~3*01,02	4*02	6.89	13	IgG	K020409	2~30*01	1*01	Undetermined
45851	3M-052-SE	PBMC	H020500	4~59*01	6~13*01	1*01	4.21	10	IgA	L020324	5~48*01	1*01	V3
45851	3M-052-SE	PBMC	H020498	5~51*01	3~10*01	5*01	4.15	13	IgG	L020327	1~50*01	2*01	V3
45851	3M-052-SE	PBMC	H020499	3~43*02	2~8*02	4*02	5.61	16	IgG	L020326	6~57*01	7*01	Undetermined
45851	3M-052-SE	PBMC	H020505	4~59*01	1~1*01	1*01	4.21	10	IgM	L020329	6~57*01	7*01	V3
45851	3M-052-SE	PBMC	H020501	4~39*06	3~3*01,02	4*02	6.63	13	IgG	L020328	5~48*01	1*01	V3
45851	3M-052-SE	PBMC	H020504	3~43*02	6~13*01	4*02	5.31	10	IgG	L020329	6~57*01	7*01	Undetermined
45851	3M-052-SE	PBMC	H020506	4~39*06	3~3*01,02	1*01	6.38	13	IgE	L020333	6~57*01	7*01	V3
45851	3M-052-SE	PBMC	H020496	3~43*02	2~8*02	4*02	5.57	16	IgG	K020407	2~40*01	1*01	Undetermined
45851	3M-052-SE	PBMC	H020497	4~59*01	1~1*01	1*01	3.95	10	IgG	K020409	2~30*01	1*01	V3

Epitope specificities and immunogenetics of vaccine-elicited Env-specific memory BCR repertoires did not differ across vaccination groups.

We next characterized the immunogenetics and epitope specificities of the HIV Env vaccine-elicited mAbs. In our initial analysis, the identification of functional heavy and light chains and their immunogenetic characteristics was conducted using a previously validated bioinformatic method for rhesus BCR repertoire characterization using the human Ig sequence database (28, 30) (Table 1). Notably, the majority of identified functional heavy- and light-chain Ig pairs were of IgG isotype (31 functional pairs) with IgA and IgM isotypes represented in 4 and 3 functional pairs, respectively (Fig 2A and Table 1). Most mAbs were specific to the HIV Env V3 loop (14 functional Ig pairs) followed by V1V2 loop-specific mAbs (5 functional pairs). Only one functional pair targeting the CD4 binding site was identified, and we were unable to determine the epitope specificities of 18 functional heavy and light chains pairs. These data are consistent with our prior observations which demonstrated that most of the polyclonal plasma antibody response in these vaccinated infant macaques was directed against the HIV Env V3 region (25, 26).

Recent advances in genome sequencing and detailed characterization of rhesus Ig loci provided better understanding of allelic diversity in rhesus Ig genes (32-34). Moreover, the availability of rhesus Ig gene libraries (32) provided the opportunity to reanalyze the 39 functional Ig pairs that we previously identified using the human Ig sequence database. This secondary analysis confirmed that 26 of 39 Ig pairs were indeed functional (Table 2) with 5 Ig pairs in group 1 (protein only), 7 Ig pairs in group 2 (coadministration), 8 Ig pairs in group 3

(extended interval), and 6 Ig pairs in group 4 (3M-052-SE) (Fig 2B). Similar to earlier analysis using the human Ig sequence database, the majority of identified functional heavy- and light-chain Ig pairs are of IgG isotype (21 functional pairs). Based on the rhesus Ig sequence database, the variable heavy chain (VH) gene usage was largely restricted to the VH3 and VH4 gene families, across all the vaccination groups, and there was no apparent difference in VH usage in the 3M-052-SE group as compared to the other vaccination groups (Table 2). The majority of the Ig pairs confirmed as functional in the secondary analysis were against undefined epitopes (12 Ig pairs), whereas 6 pairs were specific to the V3 loop and 5 pairs targeted the V1V2 loop. This suggests that an important proportion of the vaccine-elicited mAbs were against non-linear conformational epitopes on the HIV Env.

Figure 2. Epitope specificity and immunogenetic characteristics of infant vaccine-elicited envelope-specific functional heavy chain and light chain pairs. (A) Initial analysis with human immunoglobulin (Ig) database indicated a total of 39 heavy and light chain pairs isolated from antigen-specific B cells from infant PBMCs and tissues were reactive to HIV envelope (Env-reactive). Epitope specificity, VH gene family usage and isotype distribution of identified functional heavy and light chains are displayed in concentric circles. The number of mAbs per group is displayed in the center. (B) Reanalysis using newly developed software based on rhesus macaque Ig sequences confirmed that 26 of 39 heavy chain and light chain pairs were functional.

Table 2. Immunogenetic characteristics of isolated envelope (Env)-reactive mAbs of Env-vaccinated infant monkeys based on rhesus macaque immunoglobulin database analysis. A total of 26 pairs of potentially Env-reactive mAbs were isolated from the four vaccination groups across several anatomic compartments. Frequency of gene usage, percent somatic hypermutation, and complementarity-region 3 (CDR3) length are displayed for the heavy and light chains for each mAb along with the isotype and epitope specificity.

Animal ID	Group	Tissue	IgH ID	V _H gene	D _H gene	J _H gene	HC % SHM	HC CDR3 length	Ig Isotype	IgL ID	V _L /V _K gene	J _L /J _K gene	Specificity
45521	Protein Only	Spleen	H691 207	IGHV 4-j*02	IGHD 3-9*01	IGHJ 5-2*01	3.82	23	IgG	K690 414	IGKV 1-n*01	IGKJ 2-1*01	Undetermined
45521	Protein Only	Retropharyngeal LN	H691 248	IGHV 4-j*02	IGHD 3-9*01	IGHJ 5-2*01	5.21	23	IgA	K690 428	IGKV 1-n*01	IGKJ 2-1*01	Undetermined
45521	Protein Only	Retropharyngeal LN	H691 255	IGHV 4-j*03	IGHD 3-9*01	IGHJ 5-2*01	4.51	23	IgG	K690 431	IGKV 1-n*01	IGKJ 2-1*01	Undetermined
45521	Protein Only	Retropharyngeal LN	H691 256	IGHV 4-j*02	IGHD 3-9*01	IGHJ 5-2*01	3.82	23	IgG	K690 432	IGKV 1-n*01	IGKJ 2-1*01	Undetermined
45522	Protein Only	Spleen	H691 308	IGHV 4-n*01	IGHD 6-24*01	IGHJ 4*01	7.90	13	IgG	L690 936	IGLV 1-e*01	IGLJ 3*01	Undetermined
45083	Coadministration	Spleen	H691 279	IGHV 4-f*02	IGHD 6-34*01	IGHJ 4*01	7.56	13	IgM	L690 918	IGLV 1-b*01	IGLJ 3*01	V1V2
45083	Coadministration	Mediastinal LN	H691 285	IGHV 4-g*02	IGHD 3-26*01	IGHJ 4*01	4.17	17	IgG	K690 448	IGKV 1-a*01	IGKJ 2-1*01	V1V2
45083	Coadministration	Mediastinal LN	H691 285	IGHV 4-g*02	IGHD 3-26*01	IGHJ 4*01	4.17	17	IgG	L690 922	IGLV 2-i*01	IGLJ 1*01	V3

45083	Coadministration	Mediastinal LN	H691289	IGHV4-f*03	IGHD5-5*02	IGHJ4*01	5.15	13	IgG	L690925	IGLV2-a*01	IGLJ1*01	Undetermined
45091	Coadministration	Axillary LN	H691299	IGHV3-g*03	IGHD4-4*02	IGHJ6*01	6.80	14	IgG	L690932	IGLV11-a*01	IGLJ2*03	Undetermined
45091	Coadministration	Axillary LN	H691306	IGHV4-j*02	IGHD4-22*01	IGHJ4*01	5.15	17	IgG	K690454	IGKV1-e*05	IGKJ4-1*01	V3
45091	Coadministration	PBMC	H691004	IGHV3-al*01	IGHD3-3*01	IGHJ4*01	7.99	19	IgG	L690726	IGLV3-c*02	IGLJ2*03	CD4 binding site
45435	Extended Interval	Mediastinal LN	H691315	IGHV4-f*03	IGHD3-21*01	IGHJ3*01	7.22	18	IgG	K690458	IGKV1-f*04	IGKJ4-1*01	V1V2
45435	Extended Interval	Mediastinal LN	H691312	IGHV4-j*02	IGHD1-39*01	IGHJ5-1*01	5.56	16	IgG	K690456	IGKV1-n*01	IGKJ2-1*01	CD4 binding site
45435	Extended Interval	Mediastinal LN	H691321	IGHV3-al*01	IGHD3-14*01	IGHJ6*01	2.43	17	IgG	K690463	IGKV1-r*01	IGKJ2-1*01	V1V2
45435	Extended Interval	Mediastinal LN	H691322	IGHV3-r*02	IGHD6-29*01	IGHJ6*01	2.43	12	IgG	K690464	IGKV3-c*01	IGKJ1-1*01	V1V2
45441	Extended Interval	Spleen	H691341	IGHV3-y*03	IGHD4-22*01	IGHJ6*01	4.86	0	IgG	K690472	IGKV1-a*01	IGKJ1-1*01	Undetermined
45441	Extended Interval	Spleen	H691346	IGHV4-j*02	IGHD3-21*01	IGHJ4*01	13.75	0	IgG	L690948	IGLV1-e*01	IGLJ7*01	CD4 binding site
45441	Extended Interval	Spleen	H691343	IGHV3-y*03	IGHD2-25*01	IGHJ1*01	5.21	15	IgG	L690946	IGLV2-j*16	IGLJ6*01	Undetermined
45441	Extended Interval	Submental LN	H691216	IGHV4-j*02	IGHD3-3*01	IGHJ6*01	1.39	18	IgA	K690417	IGKV2-d*03	IGKJ1-1*01	Undetermined
45851	3M-052-SE	PBMC	H680141	IGHV3-l*02	IGHD5-23*01	IGHJ5-2*01	0.00	11	IgG	K680049	IGKV2-r*01	IGKJ1-1*01	Undetermined
45851	3M-052-SE	PBMC	H680144	IGHV4-m*02	IGHD1-A*01	IGHJ4*01	2.38	13	IgG	K680048	IGKV2-g*01	IGKJ1-1*01	Undetermined
45851	3M-052-SE	PBMC	H680146	IGHV4-f*02	IGHD6-24*01	IGHJ4*01	4.47	10	IgD	L680105	IGLV5-b*01	IGLJ1*01	V3
45851	3M-052-SE	PBMC	H680147	IGHV5-b*02	IGHD7-A*01	IGHJ6*01	2.43	13	IgG	L680103	IGLV1-d*01	IGLJ2*03	V3
45851	3M-052-SE	PBMC	H680149	IGHV4-f*02	IGHD6-24*01	IGHJ4*01	5.15	10	IgE	L680109	IGLV6-c*01	IGLJ2*03	V3
45851	3M-052-SE	PBMC	H680150	IGHV4-m*02	IGHD1-A*01	IGHJ4*01	2.04	13	IgG	L680108	IGLV5-b*01	IGLJ1*01	V3

Frequency of somatic hypermutation and heavy chain complementarity-determining region 3 (HCDR3) length in HIV Env-specific Ig pairs did not differ across vaccination groups.

We also sought to define whether increased somatic hypermutation and affinity maturation in Env-specific Ig pairs could potentially contributed to distinct plasma antibody responses induced by different pediatric HIV vaccine regimens (25, 26). Based on the preliminary Ig sequence analysis using the human Ig gene database, the frequency of somatic hypermutation (SHM) was

comparable across the vaccination groups (Fig 3A) with range of SMH of 5.31-10.03% in group 1 (protein only), 4.52-10.15% in group 2 (coadministration), 6.05-11.08% in group 3 (extended interval), and 4.15-7.03% in group 4 (3M-052-SE) (Table 1). Additionally, the HCDR3 of Env-reactive functional pairs were comparable across all vaccination groups, with HCDR3 length range of 10-23 aa. The highest median HCDR3 length was observed in the protein only group (median length of 23 aa) and the lowest was observed in the 3M-052-SE group (median length of 13 aa). The HCDR3 median length in group 2 (coadministration) and 3 (extended interval) was 14 aa and 17 aa, respectively.

Fig 3. Frequency of somatic hypermutation and heavy chain complementarity-determining region 3 (HCDR3) length of vaccine-elicited envelope (Env)-reactive functional heavy and light chains identified from infants. (A) Analysis of percent somatic hypermutation frequency and HCDR3 lengths for Env-reactive heavy and light chains pairs (39 mAb pairs) from infant antigen-specific B cells based on human immunoglobulin (Ig) sequence database. (B) Analysis of percent somatic hypermutation frequency and HCDR3 lengths for Env-reactive heavy and light chains pairs (26 mAb pairs) from antigen-specific B cells based on rhesus macaque Ig sequence database. Horizontal lines indicated median values of individual groups. Corresponding functional heavy and light chains isolated from individual infants are denoted by symbols.

Comparable SHM frequency across the groups was confirmed with the secondary analysis based on the rhesus Ig sequence database (Fig 3B and Table 2), albeit mutation rates were slightly lower compared to the initial analysis using the human Ig sequence database. The range of SHM was 3.82-7.9% in group 1 (protein only), 4.17-7.99% in the group 2 (coadministration), 1.39-13.75% in group 3 (extended interval), and 0-5.15% in group 4 (3M-052-SE) (Table 2). The HCDR3 length of Env-reactive functional pairs was also comparable across all vaccination groups. Similar to human Ig sequence, the highest median HCDR3 region was observed in group 1 (protein only) and the lowest median HCDR3 region was observed in group 4 (3M-052-SE). Interestingly, the median HCDR3 length in group 2 (coadministration) was lower based on human Ig sequence database (median HCDR3 length of 14 aa) than the rhesus Ig sequence (median HCDR3 length of 17 aa). Meanwhile, the median HCDR3 length for group 3 (extended interval) was lower with the rhesus IgG sequence (median HCDR3 length of 15 aa) than in the human Ig sequence (median HCDR3 length of 17 aa). These findings highlight the limitations of using human database to analyze the BCR repertoire in rhesus.

Altogether, our data suggest that the magnitude and quality of vaccine-elicited plasma Env-specific antibody responses administered with different adjuvants are not related to the size of the antigen-specific memory B cell pool or to the immunogenetics characteristics of the vaccine-elicited Ig pairs.

Discussion

Based on previous observations that different pediatric HIV vaccine regimens induced distinct plasma antibody responses (25, 26), the goal of this study was to investigate whether these responses were driven by distinct memory BCR repertoire characteristics including distinct Ig gene usage, rates of SHM and HCDR3 lengths. We utilized samples from 2 completed immunization studies (25, 26), in which newborn infant rhesus macaques were immunized with four distinct vaccine regimens (Figure 1). Our results indicate that although the different vaccine

regimens induced distinct plasma antibody responses, there were no significant differences in the B cell repertoires.

The development of a safe and effective pediatric HIV-1 vaccine to eliminate postnatal infant HIV-1 infections will probably require the use of novel adjuvants such as Toll-like receptor (TLR) agonists. Indeed, recent studies have demonstrated that TLR7/8 adjuvantation can enhance vaccine responses in early life (35-37). Notably, our group recently reported that an HIV vaccine adjuvanted with 3M-052-SE induces superior plasma antibody levels than other adjuvanted HIV regimens in infant rhesus macaques (26). We showed that antibody levels against autologous and heterologous envelope proteins, and observed that overall, the magnitude of the vaccine-elicited antibody response was higher in the 3M-052-SE group (Supplemental figure 1A-C). However, the impact of these different pediatric HIV Env vaccine regimens on the developing infant antigen-specific B cell BCR repertoires is still unclear.

Previous study investigating the BCR repertoire in HIV immunized adult monkeys have reported a preferential usage of the VH4 and VH3 families (28). Our initial analysis of the BCR repertoire in the vaccinated infant rhesus macaques was conducted using the same human Ig sequence database and bioinformatics methods, in which we similarly observed that 69% of the infant Env-specific functional heavy and light chains in this study used VH4 genes and 26% use VH3 genes (Table 1). However, we found that the Env-specific functional heavy and light chains in infant rhesus macaques were slightly shorter and had lower mutation rates than in adults. For example, in adult rhesus macaques immunized with a pox prime/protein boost regimen the median HCDR3 length after the fifth immunization was 16 aa and the SHM rate was 9.3%. Meanwhile, in our study the overall median HCDR3 length across all vaccination groups was 14 aa and the SMH rate was 6.3%. The lower levels of SHM rate in infant rhesus macaques as compared to adult rhesus macaques is in accordance with the observation that SHM rate increases with age. Moreover, broadly neutralizing antibodies (bNAbs) isolated from HIV-infected pediatric patients (1-year post-infection) also have lower levels of SHM rate than HIV-infected adult bNAbs directed against the same epitopes (38).

Due to their close genetic similarity to humans, rhesus macaques are valuable animal model for studies of infectious diseases including the understanding of vaccine-elicited immune responses. However, despite their wide usage as a human surrogate model system, many aspects of the rhesus macaque immune system are still under characterized and poorly annotated. Recent advances in high-throughput NGS and specialized computational methods provide tools to the scientific community to compare rhesus repertoires of heavy and light-chains to humans in order to better understand how they may perform as a model system for B- and T-cell mediated immunity in humans (39-41). Characterization of human and rhesus BCR repertoires showed that the frequency of V- and J-gene segment usage and HCDR3 lengths between human and rhesus were in concordance with one another (39, 42). However, comparative analyses of different Ig subtypes (IgM, IgG, IgK and IgL) sequences revealed significant differences in the overall BCR repertoires. Rhesus macaques have higher diversity of BCR repertoires with different family gene usage and slight difference in the frequencies of HCDR3 lengths within the IgM⁺ BCR repertoires, likely due to gene family usage in the class-switched (IgG) compartment (39). However, importantly, the low abundance of long CDRH3s in rhesus IgM⁺ B cells did not impede their expansion into the IgG⁺ B cells, and in rhesus IgG⁺ B cell frequency was comparable to human IgG⁺ B cells. Thus, given the complexity of gene recombination, high diversity in rhesus BCR repertoires, and the close genetic relationship between rhesus and

humans, it is likely that rhesus B-cell compartment recapitulates its human counterpart and is poised to respond to antigen in similar manners.

Historically, a limitation of BCR repertoire analysis in the nonhuman primate (NHP) model has been the lack of rhesus macaque Ig sequence database. Recent development of bioinformatics tools that enable comparison of Ig sequences from immunized animals to a NHP reference database allows for a more accurate characterization of the BCR repertoire in response to vaccination or infection. We found some differences in BCR repertoire characteristics including VH usage, SMH rate, and Ig subclass/isotypes when the same Ig pairs were analyzed using human Ig and rhesus Ig sequence databases (Figure 1A-B, Table 1-2). Notably only 26 of 39 pairs identified as functional based on the human Ig sequence database were confirmed to be functional using the rhesus Ig sequence database. This could be due to high sequence homology using the rhesus Ig sequence database compared to human Ig sequence database. These findings highlight the importance of species-specific database for comprehensive understanding of the BCR repertoire and antibody maturation in response to vaccinations and/or infections using the rhesus macaque model.

Interestingly, the observed SHM rate in infants across all vaccinations groups in this study (4.7%) is only slightly higher than the observed SHM rate in human HIV vaccine trials such as GSK PRO HIV-002 (3.8%) and the RV144 trial (2.4%). HIV-1-infected infants have been shown to develop neutralization breadth earlier than HIV-infected adults. Plasma antibody responses in HIV-infected infants neutralized a panel of diverse HIV-1 viruses, including more difficult to neutralize cross clade variants (43). Additionally, these responses were observed as early as 1 to 2 years post-infection. Furthermore, bNAbs isolated from pediatric HIV cases appeared to have lower levels of SHM when compared to bNAbs isolated from HIV-infected adults (38). Altogether, these data suggest that induction of HIV-1-specific plasma antibody neutralization can be achieved in children without prolonged extensive SHM and affinity maturation.

Conclusion

Our results suggest that the high plasma antibody magnitude and functionality achieved with 3M-052-SE adjuvantation is not accompanied by distinct B cell repertoire characteristics. Nevertheless, our study is limited by the distinct vaccine regimens used and the low number of functional heavy and light chain pairs identified from the different vaccination groups. Further investigation of the mechanism by which the 3M-052-SE adjuvant leads to enhanced immune responses in the setting of the developing early life immune system are warranted. Additionally, it will be important to evaluate whether the enhanced immunogenicity of HIV vaccines with 3M-052-SE adjuvantation in infants is associated with protection from oral virus exposure.

Acknowledgements

We would like to thank Carolyn Weinbaum for her contribution in animal study and sample coordination. Flow cytometry and single cell sorting was performed at the Duke Human Vaccine Institute (DHVI) Flow Cytometry Facility, Duke University, Durham, NC.

Funding

This work was supported by grant P01 AI117915 from the (National Institute of Allergy and Infectious Diseases (NIAID) to KDP and SRP, and P51OD011107 (Office of Research Infrastructure Program, Office of The Director, NIH) to CNPRC. SJB is supported by the Interdisciplinary Research and Training Program in AIDS (5T32AI007392-31), Duke University.

References

1. Organization WH. HIV/AIDS 2019 [Available from: <https://www.who.int/news-room/fact-sheets/detail/hiv-aids>.
2. Haas AD MM, Egger M, Tenthani L, Tweya H, Jahn A, Gadabu OJ, Tal K, Salazar-Vizcaya L, Estill J, Spoerri A, Phiri N, Chimbwandira F, van Oosterhout JJ, Keiser O. Adherence to Antiretroviral Therapy During and After Pregnancy: Cohort Study on Women Receiving Care in Malawi's Option B+ Program. Clin Infect Dis. 2016;63(9):1227-35.
3. Tenthani L HA, Tweya H, Jahn A, van Oosterhout JJ, Chimbwandira F, Chirwa Z, Ng'ambi W, Bakali A, Phiri S, Myer L, Valeri F, Zwahlen M, Wandeler G, Keiser O. Retention in care under universal antiretroviral therapy for HIV-infected pregnant and breastfeeding women ('Option B+') in Malawi. AIDS. 2014;28(4):589-98.
4. Stadeli KM RD. Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir Ther. 2015;18(1):115-23.
5. UNAIDS. Prevention Gap Report. Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland. 2016.
6. Drake AL WA, Richardson B, John-Stewart G. Incident HIV during pregnancy and postpartum and risk of mother-to-child HIV transmission: a systematic review and meta-analysis. PloS Med. 2014;11.
7. WHO. Global Update on the Health Sector Response to HIV. World Health Organization, Geneva, Switzerland. 2014.
8. Siberry GK. Preventing and managing HIV infection in infants, children, and adolescents in the United States. Pediatr Rev. 2014;35(7):268-86.
9. Gao Y, McKay PF, Mann JFS. Advances in HIV-1 Vaccine Development. Viruses. 2018;10(4).
10. Dolin R, Graham BS, Greenberg SB, Tacket CO, Belshe RB, Midthun K, et al. The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network. Ann Intern Med. 1991;114(2):119-27.
11. Wright PF, Lambert JS, Gorse GJ, Hsieh RH, McElrath MJ, Weinhold K, et al. Immunization with envelope MN rgp120 vaccine in human immunodeficiency virus-infected pregnant women. J Infect Dis. 1999;180(4):1080-8.
12. Belshe RB, Stevens C, Gorse GJ, Buchbinder S, Weinhold K, Sheppard H, et al. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. J Infect Dis. 2001;183(9):1343-52.

13. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. *N Engl J Med*. 2009;361(23):2209-20.
14. Robb ML, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Kunasol P, et al. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. *Lancet Infect Dis*. 2012;12(7):531-7.
15. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. *N Engl J Med*. 2012;366(14):1275-86.
16. Release. NIOHN. Experimental HIV Vaccine Regimen Ineffective in Preventing HIV. 3 February 2020.
17. Lin L, Finak G, Ushey K, Seshadri C, Hawn TR, Frahm N, et al. COMPASS identifies T-cell subsets correlated with clinical outcomes. *Nat Biotechnol*. 2015;33(6):610-6.
18. Johnson DC, McFarland EJ, Muresan P, Fenton T, McNamara J, Read JS, et al. Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected women. *J Infect Dis*. 2005;192(12):2129-33.
19. McFarland EJ, Johnson DC, Muresan P, Fenton T, Tomaras GD, McNamara J, et al. HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers. *AIDS*. 2006;20(11):1481-9.
20. Kaleebu P, Njai HF, Wang L, Jones N, Ssewanyana I, Richardson P, et al. Immunogenicity of ALVAC-HIV vCP1521 in infants of HIV-1-infected women in Uganda (HPTN 027): the first pediatric HIV vaccine trial in Africa. *J Acquir Immune Defic Syndr*. 2014;65(3):268-77.
21. Kintu K, Andrew P, Musoke P, Richardson P, Asiimwe-Kateera B, Nakyanzi T, et al. Feasibility and safety of ALVAC-HIV vCP1521 vaccine in HIV-exposed infants in Uganda: results from the first HIV vaccine trial in infants in Africa. *J Acquir Immune Defic Syndr*. 2013;63(1):1-8.
22. Fouda GG, Cunningham CK, McFarland EJ, Borkowsky W, Muresan P, Pollara J, et al. Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses. *J Infect Dis*. 2015;211(4):508-17.
23. Van Rompay KK, Greenier JL, Cole KS, Earl P, Moss B, Steckbeck JD, et al. Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251. *J Virol*. 2003;77(1):179-90.
24. Van Rompay KK, Abel K, Lawson JR, Singh RP, Schmidt KA, Evans T, et al. Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. *J Acquir Immune Defic Syndr*. 2005;38(2):124-34.
25. Phillips B, Fouda GG, Eudailey J, Pollara J, Curtis AD, 2nd, Kunz E, et al. Impact of Poxvirus Vector Priming, Protein Coadministration, and Vaccine Intervals on HIV gp120 Vaccine-Elicited Antibody Magnitude and Function in Infant Macaques. *Clin Vaccine Immunol*. 2017;24(10).
26. Phillips B, Van Rompay KKA, Rodriguez-Nieves J, Lorin C, Koutsoukos M, Tomai M, et al. Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques. *J Virol*. 2018;92(20).

27. Dowling DJ, van Haren SD, Scheid A, Bergelson I, Kim D, Mancuso CJ, et al. TLR7/8 adjuvant overcomes newborn hyporesponsiveness to pneumococcal conjugate vaccine at birth. *JCI Insight*. 2017;2(6):e91020.
28. Luo K, Liao HX, Zhang R, Easterhoff D, Wiehe K, Gurley TC, et al. Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques. *JCI Insight*. 2016;1(20):e88522.
29. Liao HX, Levesque MC, Nagel A, Dixon A, Zhang R, Walter E, et al. High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. *J Virol Methods*. 2009;158(1-2):171-9.
30. Wiehe K, Easterhoff D, Luo K, Nicely NI, Bradley T, Jaeger FH, et al. Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved. *Immunity*. 2014;41(6):909-18.
31. Kepler TB. Reconstructing a B-cell clonal lineage. I. Statistical inference of unobserved ancestors. *F1000Res*. 2013;2:103.
32. Ramesh A, Darko S, Hua A, Overman G, Ransier A, Francica JR, et al. Structure and Diversity of the Rhesus Macaque Immunoglobulin Loci through Multiple De Novo Genome Assemblies. *Front Immunol*. 2017;8:1407.
33. Cirelli KM, Carnathan DG, Nogal B, Martin JT, Rodriguez OL, Upadhyay AA, et al. Slow Delivery Immunization Enhances HIV Neutralizing Antibody and Germinal Center Responses via Modulation of Immunodominance. *Cell*. 2019;177(5):1153-71 e28.
34. Vazquez Bernat N, Corcoran M, Nowak I, Kaduk M, Castro Dopico X, Narang S, et al. Rhesus and cynomolgus macaque immunoglobulin heavy-chain genotyping yields comprehensive databases of germline VDJ alleles. *Immunity*. 2021;54(2):355-66 e4.
35. Holbrook BC, Aycock ST, Machiele E, Clemens E, Gries D, Jorgensen MJ, et al. An R848 adjuvanted influenza vaccine promotes early activation of B cells in the draining lymph nodes of non-human primate neonates. *Immunology*. 2018;153(3):357-67.
36. Holbrook BC, D'Agostino RB, Jr., Tyler Aycock S, Jorgensen MJ, Hadimani MB, Bruce King S, et al. Adjuvanting an inactivated influenza vaccine with conjugated R848 improves the level of antibody present at 6months in a nonhuman primate neonate model. *Vaccine*. 2017;35(45):6137-42.
37. Holbrook BC, Kim JR, Blevins LK, Jorgensen MJ, Kock ND, D'Agostino RB, Jr., et al. A Novel R848-Conjugated Inactivated Influenza Virus Vaccine Is Efficacious and Safe in a Neonate Nonhuman Primate Model. *J Immunol*. 2016;197(2):555-64.
38. Simonich CA, Williams KL, Verkerke HP, Williams JA, Nduati R, Lee KK, et al. HIV-1 Neutralizing Antibodies with Limited Hypermutation from an Infant. *Cell*. 2016;166(1):77-87.
39. Vigdorovich V, Oliver BG, Carbonetti S, Dambrauskas N, Lange MD, Yacoob C, et al. Repertoire comparison of the B-cell receptor-encoding loci in humans and rhesus macaques by next-generation sequencing. *Clin Transl Immunology*. 2016;5(7):e93.
40. Brochu HN, Tseng E, Smith E, Thomas MJ, Jones AM, Diveley KR, et al. Systematic Profiling of Full-Length Ig and TCR Repertoire Diversity in Rhesus Macaque through Long Read Transcriptome Sequencing. *J Immunol*. 2020;204(12):3434-44.
41. Zhang W, Li X, Wang L, Deng J, Lin L, Tian L, et al. Identification of Variable and Joining Germline Genes and Alleles for Rhesus Macaque from B Cell Receptor Repertoires. *J Immunol*. 2019;202(5):1612-22.

42. Dai K, He L, Khan SN, O'Dell S, McKee K, Tran K, et al. Rhesus Macaque B-Cell Responses to an HIV-1 Trimer Vaccine Revealed by Unbiased Longitudinal Repertoire Analysis. *mBio*. 2015;6(6):e01375-15.
43. Goo L, Chohan V, Nduati R, Overbaugh J. Early development of broadly neutralizing antibodies in HIV-1-infected infants. *Nat Med*. 2014;20(6):655-8.

Supplemental Figures Legends

S1 Fig. Characterization of vaccination-induced plasma envelope IgG responses in infant rhesus macaques. Envelope binding IgG responses against 1086d7gp120K160N by ELISA. (A) Peak immunogenicity gp120 specific IgG responses by ELISA. (B) Variable and conserved epitope specific IgG responses at peak immunogenicity by BAMA. (C) Avidity 1/k off (the inverse of the dissociation rate) was plotted as a measure of the strength of binding and avidity scores which take into consideration the magnitude are also shown. (D) Overall, the 3M-052 group had higher magnitude of binding antibody responses and higher avidity strength against most of the tested antigens. * denoted significant p-values ($p < 0.05$) by Mann-Whitney U Test, FDR-adjusted. Data published in Phillips et al., 2017 and Phillips et al., 2018.

S2 Fig. Frequency of Env-specific memory B cells in sorted tissues and PBMCs of envelope-vaccinated infant monkeys. (A) Percentage of memory B cells (CD20+CD27+IgD-), which are envelope-specific double positive cells for 1086.C gp120 (tagged with two colors-BV421 and AF647) for single-cell sorting. (B) Representative gating strategy for single-cell HIV Env-specific memory B cell sorting by flow cytometry.

Group 1: Protein only
MVA-SIV gag/pol (5×10^8 IU, IM) [●] +
HIV Env 1086c (15ug STS adjuvant, IM +
200ug R484 adjuvant, IN) [■]
(n = 5)

Group 2: Coadministration
MVA-SIV gag/pol (5×10^8 IU, IM) [●] +
HIV Env 1086c (15ug STS adjuvant, IM +
200ug R484 adjuvant, IN) [■]
MVA-HIV Env (5×10^8 IU, IM) [▼], (n = 5)

Group 3: Extended Interval
MVA-SIV gag/pol (5×10^8 IU, IM) [●] +
HIV Env 1086c (15ug STS adjuvant, IM +
200ug R484 adjuvant, IN) [■]
MVA-HIV Env (5×10^8 IU, IM) [▼], (n = 5)

Group 4: 3M-052-SE
HIV Env 1086c/Tv1 bivalent (IM) [◆] +
3M-052-SE [◆]
(n = 4)

Figure 1

Figure 2

Figure 3